Characterization of insulin secretion in Valproate-treated patients with epilepsy.
about
Inhibitory effect of valproic acid on ovarian androgen biosynthesis in rat theca-interstitial cellsSox5 regulates beta-cell phenotype and is reduced in type 2 diabetesComparison of the metabolic syndrome risk in valproate-treated patients with epilepsy and the general population in Estonia.Polycystic ovary syndrome in women using valproate: a review.Neuroendocrine considerations in the treatment of men and women with epilepsyTargeting histone deacetylases for the treatment of diseaseHistone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus.Weight change, genetics and antiepileptic drugs.Treating epilepsy in the setting of medical comorbidities.Antiepileptic drugs influences on body weight in people with epilepsy.Does Valproic Acid Have Potential in the Treatment of Diabetes Mellitus?Chronic exposure to valproic acid promotes insulin release, reduces KATP channel current and does not affect Ca (2+) signaling in mouse islets.Weight gain and insulin resistance in children treated with valproate: the influence of time.Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls.Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients.Evaluation of adiponectin and leptin levels and oxidative stress in bipolar disorder patients with metabolic syndrome treated by valproic acid.Thiopental-induced insulin secretion via activation of IP3-sensitive calcium stores in rat pancreatic β-cells.
P2860
Q29347087-EC3AD1D0-2642-4689-9519-1D3627AFDF95Q33786322-A88AE254-C11A-4A7A-87AC-58E9B597B2C6Q33982437-AF28A1FF-5901-49EF-B375-FFAB74B89B1BQ34881401-1ACE2B03-E62B-4CB3-B7A2-388FFD62EA7BQ37055791-C7B16722-B950-4D26-A1AC-552FF0C76547Q37296159-54AAC74E-C3C9-44EB-B933-115F1F823DB5Q37832964-F94AAB6E-A6CC-48F3-BE82-AC56FEB20F16Q38168942-3D8A9AD8-6233-4690-831E-E27AE0F963A2Q38214818-7F1BD048-DDF8-49FA-9381-98BAB39B8E58Q38285318-8F77147A-C1AC-4EAC-9E87-A6FBE8664668Q41049740-F6023E12-B591-40A8-8BF2-6860269B9E6CQ42446162-04EFB926-7947-4CD5-B9A9-14AE358BC179Q43140659-0139ED83-4E3B-499D-BD7D-DCEED6D56DB8Q43996934-69666A94-302F-4496-A885-4D86F528E98EQ46780453-BB8564AE-0798-4654-B917-F7398D32F23FQ47628823-FAE1A98F-497C-4B2E-A015-1BA5567DC5B9Q48208351-DCA87CAC-2697-4035-844B-84B9C01ACF49
P2860
Characterization of insulin secretion in Valproate-treated patients with epilepsy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Characterization of insulin secretion in Valproate-treated patients with epilepsy.
@en
Characterization of insulin secretion in Valproate-treated patients with epilepsy.
@nl
type
label
Characterization of insulin secretion in Valproate-treated patients with epilepsy.
@en
Characterization of insulin secretion in Valproate-treated patients with epilepsy.
@nl
prefLabel
Characterization of insulin secretion in Valproate-treated patients with epilepsy.
@en
Characterization of insulin secretion in Valproate-treated patients with epilepsy.
@nl
P2093
P2860
P1433
P1476
Characterization of insulin secretion in Valproate-treated patients with epilepsy.
@en
P2093
Arto Pakarinen
Jouko Isojärvi
Virpi Pylvänen
P2860
P304
P356
10.1111/J.1528-1167.2006.00546.X
P50
P577
2006-09-01T00:00:00Z